Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 11/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7154833 | 0.84 | GAA (0.49) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL1556955 | 0.83 | GAA (0.60) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL4221206 | 0.82 | BRD4 (0.66) | GAAPKMSMYD3IDO1MAPT | |
| SCHEMBL3249974 | 0.81 | GAA (0.54) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL7127247 | 0.81 | GRIA1 (0.54) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL2203244 | 0.80 | GAA (0.64) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL10293161 | 0.80 | GAA (0.60) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL517067 | 0.80 | GAA (0.60) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL689168 | 0.80 | GAA (0.60) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL4896390 | 0.80 | PKM (0.57) | GAAPKMSMYD3IDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266855-A1 | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-6777417-B2 | ANTICANCER AGENTS | SUGEN, INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1436259-A1 | 3-(4,5,6,7-TETRAHYDROINDOL-2-YLMETHYLIDIENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | Liang, Congxin (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2003022815-A1 | 3-(4,5,6,7-TETRAHYDROINDOL-2-YLMETHYLIDIENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266855-A1 | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors | SRC, LCK, MAP3K20 | GAA 2494/4885PKM 606/4885AHR 1786/4885 |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SRC, LCK, MAP3K20 | GAA 2819/4885PKM 653/4885AHR 1559/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | GAA 3834/4885PKM 951/4885AHR 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.